Sorrento Therapeutics, Inc. SRNE
Recently we’ve been delving back into our reports from late 2017, to review the ones that have made notable moves, and next up on the list SRNE.
We last signaled our interest in this as a bottom-watch play back on November 16th, and while it took a couple weeks for it to get out of its sideways-trading funk, the beginning of December brought the start of a fantastic run from an ultimate low of 2.15 that has persisted into the present. Yesterday the stock reached a new annual high of 8.05 (highest PPS since October ’16), marking an increase of 274%
This most recent push in what has definitely been a steady but sharp rise of the past six weeks may have been helped along by Celgene’s (CELG) buyout of Juno Therapeutics (JUNO), which share a market space with SRNE. The company also has some promising treatments in its pipeline.
Volume has recently been ramping up in a big way, too, so we’ll definitely continue to have an eye on this stock’s activity.
Netflix, Inc. NFLX – Options Idea
We’re always looking for a good opportunity to make some quick gains in the wake of a big company’s earnings, and NFLX is one that we’ve had quite a bit of experience with in that arena.
That’s why we’re going to enter an idea into the log this morning in the NFLX Weekly $247.50-255 Calls as the company posted a promising report including the addition of more than eight million new subscribers even despite its recent price increases.
Shares of NFLX broke a double top and are in blue skies, hitting a new all time high, so we’re very interested to track the ideas we’ve identified. They may be able to furnish us with some impressive gains.
CNET, ROKU, FATE, RMD, FNJN, VYGR